Lacosamide
Brand names: Lacosamide, Motpoly Xr, Vimpat
At a glance
- Medicare prescriptions, 2024
- 733,681
- Medicare drug cost
- $129.2M
- Average cost per prescription
- $176
- Clinicians who prescribed it
- 16,829
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
VIMPAT is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 53.2%
- Nurse Practitioners 21.5%
- Internal Medicine 7.7%
- Family Medicine 6.5%
- Physician Assistants 5.5%
- Geriatric Medicine 1.3%
- Child Neurology 0.7%
- General Practice 0.5%
- Psychiatry 0.3%
- Physical Medicine & Rehabilitation (PM&R) 0.3%
- Sleep Medicine 0.3%
- Hospitalist 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 28% from 2019 to 2024.
Biggest change by state since 2019
- Oregon +65%
- Washington +57%
- Kansas +50%
- Minnesota +48%
- Tennessee +46%
- Nebraska (smallest change) −3%
- Iowa (smallest change) +8%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow solution | |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow solution | |
Florida Pharmaceutical Products, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow solution | |
UCB, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow solution | |
| 50 mg | pink oval tablet, 10 mm | SP 50 |
| 100 mg | yellow oval tablet, 13 mm | SP 100 |
| 150 mg | orange oval tablet, 15 mm | SP 150 |
| 200 mg | blue oval tablet, 16 mm | SP 200 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $121,964 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Aucta Pharmaceuticals, Inc. $121,885
- UCB, Inc. $79
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
4 recalls since 2020
- Jun 2026 · Annora Pharma Private Limited · Class II
Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg. - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Dec 2022 · Camber Pharmaceuticals, Inc · Class III
Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Industry-funded trials
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures Terminated · UCB SA
- Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures Completed · UCB Biosciences Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.